We have collected information about Of Recurrent Preterm Delivery By 17 Alpha Hydroxyprogesterone Caproate for you. Follow the links to find out details on Of Recurrent Preterm Delivery By 17 Alpha Hydroxyprogesterone Caproate.
https://www.nejm.org/doi/full/10.1056/NEJMoa035140
Original Article from The New England Journal of Medicine — Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone CaproateAuthor: Paul J. Meis, Mark Klebanoff, Elizabeth Thom, Mitchell P. Dombrowski, Baha Sibai, Atef H. Moawad, Ca...
https://www.ncbi.nlm.nih.gov/pubmed/12802023
Jun 12, 2003 · The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery. METHODS: We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of …Author: Paul J. Meis, Mark Klebanoff, Elizabeth Thom, Mitchell P. Dombrowski, Baha Sibai, Atef H. Moawad, Ca...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449222/
Study Design. This was a prospective cohort study of 17-alpha hydroxyprogesterone caproate in our obstetric population. The primary outcome was the recurrence of birth ≤ 35 weeks for the entire study cohort compared to a historical referent rate of 16.8% of recurrent preterm birth in our population.Author: David B. Nelson, Donald D. McIntire, Jeffrey McDonald, John Gard, Paula Turrichi, Kenneth J. Leveno
https://www.smfm.org/publications/280-smfm-statement-use-of-17-alpha-hydroxyprogesterone-caproate-for-prevention-of-recurrent-preterm-birth
SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth
https://www.astho.org/Maternal-and-Child-Health/17P-Fact-Sheet/
17 Alpha-hydroxyprogesterone caproate (17P) Making the Case for 17P . Nearly 500,000 1babies are born preterm in the United States each year. Preterm birth (PTB), or birth less than 37 weeks gestation, puts infants at a higher risk of death and is the leading cause of longterm - …
https://www.sciencedirect.com/science/article/pii/S0002937817302946
Study Design. This was a prospective cohort study of 17-alpha hydroxyprogesterone caproate in our obstetric population. The primary outcome was the recurrence of birth ≤35 weeks for the entire study cohort compared to a historical referent rate of 16.8% of recurrent preterm birth in our population.Author: David B. Nelson, Donald D. McIntire, Jeffrey McDonald, John Gard, Paula Turrichi, Kenneth J. Leveno
https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.14485
Jan 31, 2017 · Objective. To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17‐alpha hydroxyprogesterone caproate (17‐P) administration for the prevention of recurrent preterm birth (PTB).Author: TA Manuck, TA Manuck, TA Manuck, WS Watkins, Esplin, Esplin, J Biggio, R Bukowski, S Parry, H Zhan, ...
https://researchers.dellmed.utexas.edu/en/publications/pharmacogenomics-of-17-alpha-hydroxyprogesterone-caproate-for-rec
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth : a case–control study. / the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
https://www.sciencedirect.com/science/article/pii/S000293781400026X
458 rows · Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth …Author: Tracy Ann Manuck, Tracy Ann Manuck, W. Scott Watkins, Barry Moore, M. Sean Esplin, M. Sean Esplin, M...
Searching for Of Recurrent Preterm Delivery By 17 Alpha Hydroxyprogesterone Caproate?
You can just click the links above. The data is collected for you.
